A Look At AbCellera Biologics (ABCL) Valuation After Its Planned ABCL635 Phase 1 Data Update

Simply Wall St.04-24 02:14

AbCellera Biologics (ABCL) has drawn fresh attention after announcing plans to share interim Phase 1 data for its menopause therapy candidate ABCL635 during its first quarter 2026 earnings call on May...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629310857?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-04-24 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629310857","market":"nz","top_or_hot":-1,"title":"A Look At AbCellera Biologics (ABCL) Valuation After Its Planned ABCL635 Phase 1 Data Update","media":"Simply Wall St.","content":"<div>\n<p>AbCellera Biologics (ABCL) has drawn fresh attention after announcing plans to share interim Phase 1 data for its menopause therapy candidate ABCL635 during its first quarter 2026 earnings call on May...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-its-plann\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At AbCellera Biologics (ABCL) Valuation After Its Planned ABCL635 Phase 1 Data Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At AbCellera Biologics (ABCL) Valuation After Its Planned ABCL635 Phase 1 Data Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-24 02:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-its-plann><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbCellera Biologics (ABCL) has drawn fresh attention after announcing plans to share interim Phase 1 data for its menopause therapy candidate ABCL635 during its first quarter 2026 earnings call on May...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-its-plann\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-its-plann","article_id":"2629310857","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/a-look-at-abcellera-biologics-abcl-valuation-after-its-plann","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629310857","pubTimestamp":1776968054,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AbCellera Biologics (ABCL) has drawn fresh attention after announcing plans to share interim Phase 1 data for its menopause therapy candidate ABCL635 during its first quarter 2026 earnings call on May 11.\nSee our latest analysis for AbCellera Biologics.\nThe recent ABCL635 update comes after a mixed stretch for the stock, with a 21.07% 1 month share price return and 18.95% year to date share price return contrasting with a 12.07% 3 month decline. The 61.26% 1 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","ABCL":"AbCellera Biologics","BK4121":"生命科学工具和服务"},"translate_title":"AbCellera Biologics(ABCL)计划更新ABCL635 1期数据后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1.5},"content_text":"AbCellera Biologics (ABCL) has drawn fresh attention after announcing plans to share interim Phase 1 data for its menopause therapy candidate ABCL635 during its first quarter 2026 earnings call on May 11. See our latest analysis for AbCellera Biologics. The recent ABCL635 update comes after a mixed stretch for the stock, with a 21.07% 1 month share price return and 18.95% year to date share price return contrasting with a 12.07% 3 month decline. The 61.26% 1 year total shareholder return hints at improving sentiment despite weaker multi year total shareholder returns. If this kind of early stage drug pipeline story interests you, it can be worth widening the lens to other healthcare names using our screener for 35 healthcare AI stocks With AbCellera trading at US$4.08 and analyst targets sitting higher, along with mixed recent returns and ongoing losses, the real question is whether the current price reflects the whole ABCL635 story or if the market is already assuming future growth. AdvertisementMost Popular Narrative: 58.5% Undervalued With AbCellera Biologics last closing at $4.08 and the widely followed fair value sitting at $9.83, the current price sits well below that narrative anchor, putting extra weight on how the ABCL635 and broader pipeline story plays out.  The initiation of Phase I clinical trials for ABCL635 and ABCL575, with promising differentiation factors such as a unique dosing regimen and improved safety profile for ABCL635, is expected to position the company to capture a significant market opportunity in an underserved area, potentially boosting future revenue.  Read the complete narrative. Curious how a still unprofitable biotech can screen as this undervalued? The narrative leans on aggressive revenue expansion, margin uplift and a rich future earnings multiple. The tension between those assumptions and today’s losses is exactly where the full story gets interesting. Result: Fair Value of $9.83 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story could shift quickly if ABCL635 underdelivers in the clinic or if high R&D spend and widening losses keep pressure on cash and sentiment. Find out about the key risks to this AbCellera Biologics narrative. Another Way To Look At The Valuation The fair value narrative paints AbCellera as 58.5% undervalued at $9.83. However, the current P/S ratio of 16.5x tells a very different story versus the US Life Sciences industry at 3.2x, peers at 4.2x and a fair ratio of just 0.2x. This raises the question of who is really out of line, the model or the market. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ABCL P/S Ratio as at Apr 2026Next Steps If this mix of optimism and caution feels hard to balance, treat it as a prompt to check the numbers yourself. Move quickly to form an independent view, starting with the 2 important warning signs. Looking for more investment ideas? If AbCellera has caught your eye, do not stop here. Broaden your watchlist with other focused ideas that match the way you like to invest.  Target reliable income by scanning companies that score as 13 dividend fortresses and decide which yields fit your goals. Hunt for potential bargains using the screener containing 23 high quality undiscovered gems and spot businesses the market may be overlooking. Prioritise resilience first and shortlist candidates via the 73 resilient stocks with low risk scores before committing fresh capital.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629310857","isCrawlerRequest":true}